UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Purchasing silence

Annals of oncology, 2018-06, Vol.29 (6), p.1339-1340

2018

Volltextzugriff (PDF)

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

European journal of cancer (1990), 2019-01, Vol.107, p.1-7

2019

Volltextzugriff (PDF)

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Annals of oncology, 2013-12, Vol.24 (12), p.2972-2977

2013

Volltextzugriff (PDF)

Topological data analysis reveals a core gene expression backbone that defines form and function across flowering plants

PLoS biology, 2023-12, Vol.21 (12), p.e3002397-e3002397

2023

Volltextzugriff (PDF)

Integrative Teaching of Metabolic Modeling and Flux Analysis with Interactive Python Modules

Biochemistry and molecular biology education, 2023-11, Vol.51 (6), p.653-661

2023

Volltextzugriff (PDF)

PO-0847 Rapid modulation of PSMA expression by ADT: Serial PSMA PET in men commencing androgen blockade

Radiotherapy and oncology, 2019-04, Vol.133, p.S445-S446

2019

Volltextzugriff (PDF)

Treatment of octogenarians with castration-resistant prostatecancer with abiraterone and docetaxel

Journal of geriatric oncology, 2013-10, Vol.4, p.S34-S34

2013

Volltextzugriff (PDF)

Anti-recombination function of MutSα restricts telomere extension by ALT-associated homology-directed repair

Cell reports (Cambridge), 2021-12, Vol.37 (10), p.110088-110088, Article 110088

2021

Volltextzugriff (PDF)

640TiP Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F

Annals of oncology, 2021-09, Vol.32, p.S669-S670

2021

Volltextzugriff (PDF)

641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H

Annals of oncology, 2021-09, Vol.32, p.S670-S671

2021

Volltextzugriff (PDF)

639TiP KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE)

Annals of oncology, 2021-09, Vol.32, p.S669-S669

2021

Volltextzugriff (PDF)

165 (PB153): NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)

European journal of cancer (1990), 2024-10, Vol.211, p.114686, Article 114686

2024

Volltextzugriff (PDF)

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2014-03, Vol.25 (3), p.657-662

2014

Volltextzugriff (PDF)

Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative

Annals of oncology, 2017-09, Vol.28, p.v439-v439

2017

Volltextzugriff (PDF)

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)

Annals of oncology, 2023-10, Vol.34, p.S1014-S1014

2023

Volltextzugriff (PDF)

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Annals of oncology, 2023-10, Vol.34, p.S1325-S1325

2023

Volltextzugriff (PDF)

1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?

Annals of oncology, 2023-10, Vol.34, p.S991-S991

2023

Volltextzugriff (PDF)

1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2023-10, Vol.34, p.S988-S989

2023

Volltextzugriff (PDF)

Flux-Balance Analysis and Mobile CRISPRi-Guided Deletion of a Conditionally Essential Gene in Shewanella oneidensis MR‑1

ACS synthetic biology, 2022-10, Vol.11 (10), p.3405-3413

2022

Volltextzugriff (PDF)

Telomere Length Measurement by Molecular Combing

Frontiers in cell and developmental biology, 2020-06, Vol.8, p.493-493

2020

Volltextzugriff (PDF)

Hückel theory and distinguishing between isospectral molecules: 1,4-divinylbenzene and 2-phenylbutadiene, and tetramethylenemethane and cyclobutadiene + carbon

Structural chemistry, 2020-06, Vol.31 (3), p.1119-1124

2020

Volltextzugriff (PDF)

LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial

Annals of oncology, 2023-10, Vol.34, p.S1289-S1290

2023

Volltextzugriff (PDF)

1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials

Annals of oncology, 2020-09, Vol.31, p.S764-S764

2020

Volltextzugriff (PDF)

KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC)

European urology, 2022-02, Vol.81, p.S789-S790

2022

Volltextzugriff (PDF)

577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2021-09, Vol.32, p.S626-S627

2021

Volltextzugriff (PDF)

26 – 50 von 270

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(252)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Englisch
(269)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(193)
Life Sciences & Biomedicine
(134)
Humans
(68)
Physical Sciences
(42)
Animals
(30)
Male
(29)
Environmental Sciences
(28)
Environmental Sciences & Ecology
(28)
Science & Technology - Other Topics
(27)
Oncology
(26)
Climate Change
(24)
Multidisciplinary Sciences
(24)
Female
(23)
Agriculture
(19)
Technology
(18)
Agricultural Production
(17)
Crops
(17)
Adult
(16)
Crop Yield
(16)
Sciences Of The Universe
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Purchasing silence

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Topological data analysis reveals a core gene expression backbone that defines form and function across flowering plants

Integrative Teaching of Metabolic Modeling and Flux Analysis with Interactive Python Modules

PO-0847 Rapid modulation of PSMA expression by ADT: Serial PSMA PET in men commencing androgen blockade

Treatment of octogenarians with castration-resistant prostatecancer with abiraterone and docetaxel

Anti-recombination function of MutSα restricts telomere extension by ALT-associated homology-directed repair

640TiP Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F

641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H

639TiP KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE)

165 (PB153): NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?

1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Flux-Balance Analysis and Mobile CRISPRi-Guided Deletion of a Conditionally Essential Gene in Shewanella oneidensis MR‑1

Telomere Length Measurement by Molecular Combing

Hückel theory and distinguishing between isospectral molecules: 1,4-divinylbenzene and 2-phenylbutadiene, and tetramethylenemethane and cyclobutadiene + carbon

LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial

1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials

KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC)

577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Suchergebnisse filtern